Hologic (NASDAQ:HOLX) Cut to “Neutral” at Citigroup

Citigroup lowered shares of Hologic (NASDAQ:HOLX – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, Marketbeat.com reports. They currently have $85.00 price objective on the medical equipment provider’s stock, down from their prior price objective of $95.00. Other equities research analysts have also issued research […]

Leave a Reply

Your email address will not be published.

Previous post National Health Investors (NYSE:NHI) Stock Rating Lowered by Wells Fargo & Company
Next post Wolfe Research Begins Coverage on Incyte (NASDAQ:INCY)